The study emulated a target trial in TriNetX US network records, 2021-2024. Non-diabetic adults with obesity and chronic kidney disease stages 3-5 were included. Semaglutide, liraglutide or tirzepatide users were matched to unexposed patients, 7,326 per cohort. One-year incident atrial fibrillation was 1.63% versus 2.62%, hazard ratio 0.655 (95% CI 0.508-0.844). Ventricular tachyarrhythmias (HR 0.556) and all-cause hospitalisation (HR 0.668) were also lower. Being retrospective, confounding by indication and unmeasured prescribing differences cannot be excluded.
Why it is interesting: It extends GLP-1 receptor agonist outcomes beyond diabetes to a cardiorenal group. Atrial fibrillation, ventricular arrhythmias and hospitalisation were all lower in treated patients.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.
Other drivers in Health today
-
Cancer
Where is cancer incidence rising and falling, what screening and new tests find earlier, and what treatment has done to survival.
8 this week -
Obesity, diabetes and GLP-1
Are obesity and diabetes still rising, what behavioural change and public policy do, and what difference do GLP-1s and other similar drugs make.
11 this week -
Heart and stroke
Whether deaths from heart disease and stroke have stopped falling, what is found earlier, what treatment and prevention do now, and what the deaths say.
5 this week -
Mental health
Deaths by suicide, the life expectancy gap in severe mental illness, and the physical disease that follows it: what mental illness costs in lives.
2 this week -
Dementia
Whether dementia is becoming more or less common, what is now found, what treatment and prevention do, and what the deaths say.
4 this week -
Frailty and multimorbidity
Whether the years added after 85 are healthy ones, how frailty and multiple conditions are measured, and where the data run out.
1 this week
